WallStSmart
ELAN

Elanco Animal Health

NYSE: ELAN · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC

$21.80
-1.58% today

Updated 2026-04-29

Market cap
$10.89B
P/E ratio
P/S ratio
2.31x
EPS (TTM)
$-0.47
Dividend yield
52W range
$9 – $28
Volume
5.1M

Elanco Animal Health (ELAN) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
7 of 8
Last 8 quarters
Avg EPS surprise
+28.1%
Last 4 quarters
Revenue YoY growth
+12.2%
Most recent quarter
EPS YoY growth
-7.1%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
+4.8%
Last 3 reports
Positive reaction rate
33%
1 of 3 quarters
Largest single-day move
+19.5%
2025-08-07
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-02-25$0.13+14.5%$26.38$26.19-0.7%
2025-11-05$0.19+46.2%$22.50$21.52-4.4%
2025-08-07$0.26+30.0%$13.95$16.67+19.5%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$0.11$0.13+14.5%$1.14B+12.2%
2025-09-30$0.13$0.19+46.2%$1.14B+10.4%
2025-06-30$0.20$0.26+30.0%$1.24B+4.8%
2025-03-31$0.30$0.37+21.6%$1.19B-1.0%
2024-12-31$0.15$0.14-5.8%$1.02B-1.4%
2024-09-30$0.12$0.13+8.3%$1.03B-3.6%
2024-06-30$0.24$0.30+25.0%$1.18B+12.0%
2024-03-31$0.26$0.34+30.8%$1.21B
2023-12-31$0.11$0.08-27.3%$1.03B
2023-09-30$0.12$0.18+50.0%$1.07B
2023-06-30$0.05$0.18+260.0%$1.06B

Frequently asked questions

Has Elanco Animal Health beaten earnings estimates?
Elanco Animal Health has beaten Wall Street EPS estimates in 7 of its last 8 quarterly reports, with an average EPS surprise of +28.1% over the last 4 quarters.
How does ELAN stock react to earnings?
ELAN stock has moved an average of +4.8% in the trading day following earnings over its last 3 reports, with positive reactions in 33% of those quarters.
What is Elanco Animal Health's revenue growth rate?
Elanco Animal Health reported year-over-year revenue growth of +12.2% in its most recent quarter, with EPS growing -7.1% year-over-year.